Subject medical patients

Theberge,J.,Al-Semaan,Y.,Williamson, P.C. etal. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am. J. Psychiat. 160 2231-2233, 2003. 

Clearly, there is an ethical question as to whether the foreseeable risks and inconveniences to a study subject or patient participating in a clinical trial are outweighed by the anticipated benefits to that patient. Even more critical is the question of whether the risks being undertaken by the healthy volunteer are considered acceptable when the volunteer will not benefit medically. 

Ideally an observed value in an individual should be related to relevant collections of reference values, such as values from healthy persons, from the undifferentiated hospital population, from persons with typical diseases, and fi om ambulatory individuals, and previous values from the same subject. A patient s laboratory result simply is not medically useful if appropriate data for comparison are lacking. 

I Dose-finding studies of new medications to determine acute toxicity. Healthy subjects or patients. These studies warrant close REB review with continuous monitoring independent of the trial sponsor. This is especially important as more of these trials include patients refractory to standard therapy, and with the increasing number of new medications. Unexpected adverse events tu e a major concern. 

The general population can tolerate high levels of dietary iodine (Pennington, 1990), but discrete populations of patients are known to be at increased risk for thyroid-related AEs as a result of iodine therapy (Braverman, 1994). The inclusion-exclusion criteria for the safety studies of I2 in iodine-naive subjects eliminated patients known to be at risk. Euthyroid patients with (a) no history of thyroid disease, (b) no previous exposure to I2, and (c) no concomitant iodine-containing medications, were eligible for inclusion in these safety trials (MX02-CLN-07 and MX02-CLN-09). The first placebo-controlled study was conducted for 6 months and the second for 12 months. 

The clearance of caffeine was about twofold higher and its half-life was reduced by about 50% in patients with epilepsy taking phenytoin, when compared with healthy subjects not taking any medications. In the same study, there were no significant differences in caffeine pharmacokinetics between healthy subjects and patients receiving carbamazepine or sodium valproate. Conversely, carbamazepine was considered to have induced the metabolism of caffeine in 5 children with epilepsy, as assessed by the caffeine breath test. In another study in healthy subjects, there was a reduction in the AUC of carbamazepine when it was given with caffeine, but caffeine had no effect on the pharmacokinetics of sodium valproate. ... 

Notify a physician immediately. A suggested procedure for physicians or nurses is intravenous administration of 0.3 g (10 mL of a 3% solution) of sodium nitrite at the rate of 2.5 mL/min followed by 12.5 g (50 mL of a 25% solution) of sodium thiosulfate at the same rate. Watch the patient for 24 to 48 h, especially in cases of ingestion or skin absorption. If symptoms reappear, repeat the injections in half the original amounts. These solutions should be kept readily available. In some cases, first aid personnel have been trained to use the intravenous medication subject to government regulations. 

Quality management is both a technical subject and a behavioral subject. It is not a bureaucratic administrative technique. The rise in popularity of ISQ 9000 has created some unhelpful messages such as the document what you do strategy. There has also been a perception in the service industries that ISQ 9000 quality systems only deal with the procedural aspects of a service and not the professional aspects. For instance in a medical practice, the ISQ 9000 quality system is often used only for processing patients... 

An ongoing assessment is one that is made at the time of each patient contact and may include the collection of objective data, subjective data, or both. The scope of an ongoing assessment depends on many factors, such as the patient s diagnosis, the severity of illness, the response to treatment, and the prescribed medical or surgical treatment. 

Kranzler and Van Kirk (2001) included 11 acamprosate studies in a metaanalysis involving more than 3,000 subjects. The magnitude of the advantage shown by acamprosate over placebo in those studies varied as a function of the outcomes examined, which included the percentage of patients who were abstinent throughout the study, cumulative abstinent days, and the rate of study retention, all of which favored the active medication. Acamprosate yielded outcomes that were, on average, 7%—13% better than those shown by individuals who received placebo. 

---